On January 9, 2026, Link Cell Therapies, an oncology cell therapy company, announced a strategic collaboration with Johnson & Johnson to develop novel logic-gated LINK CAR T therapies. The collaboration follows the recently announced Series A financing in Link that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc., which included participation of additional strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the matter.

The collaboration aims to develop AND-gate CAR T programs for clinical use by leveraging Link’s proprietary LINK logic gate, a novel technology that allows for the safe and potent killing of tumor cells.

The Wilson Sonsini team that advised Link Cell Therapies on the transaction was Norm Hovijitra, Jordin Wilcher, Alex DeLaney, Lou Lieto, Laurie McNamara, Alicia Umpierre, Ryan Lin, Christina Poulsen, Sean Mihaljevich, and Angelica Lee.

For more information, please see Link Cell Therapies’ news release.